Linkgenesis

Founded in 2003, Linkgenesis listed on KONEX in 2016 before moving to KOSDAQ in 2018. Its core business rests on two pillars: production information automation (smart factory) and system verification automation.

The production automation segment centers on developing and supplying software that standardizes SECS/GEM-based communication between semiconductor and display production equipment and host computers, addressing the standardization needs of fabs that operate large numbers of diverse machines.

The verification automation segment supplies its MAT automated test solution, built primarily around black-box testing of external software functions, and has offered an AI-enhanced MAT AI version since 2018.

More recently the company has rolled out its proprietary AI vision analytics solution VLAD, the VLAD Ops management platform, and the EQlizer platform, which integrates software automation, hardware control, and AI recognition, extending its reach into quality inspection and industrial safety.

Reported major clients have included global names such as Samsung Electronics, Hyundai Motor, and Olympus.

In February 2023, IDIS Powertel (formerly KT Powertel), part of the IT security group IDIS, acquired a 20.66% stake for about KRW23.6 billion and became the largest shareholder, later raising its stake further through market purchases.

In terms of competitive positioning, peers cited in the smart factory software and machine vision space include Withtec, Grecter, RTM, and Ensys.

The company also runs subsidiaries such as consulting firm Link Investment, measurement automation firm Bumgam, and self-learning AI firm MSYSLab, reflecting group-level diversification alongside the core business.

Annual results have shown pronounced swings. In 2022, revenue of KRW17.27 billion and operating profit of KRW3.64 billion produced a high 21.1% operating margin, but in 2023 revenue fell to KRW14.19 billion and operating profit declined to KRW1.40 billion (9.9% margin).

In 2024, revenue shrank further to KRW13.10 billion and the company swung to an operating loss of KRW0.08 billion (-0.6% margin) with an owners' net loss of KRW0.43 billion.

In 2025, revenue rebounded 29.6% year-over-year to KRW16.98 billion, and the company returned to profit with operating income of KRW1.22 billion (7.2% margin) and owners' net income of KRW2.80 billion.

Looking at recent quarters, revenue of KRW3.45 billion and operating profit of KRW0.27 billion in 2025Q2 rose to KRW3.93 billion and KRW0.61 billion in Q3, then revenue jumped to KRW6.54 billion in Q4—the year's largest quarter—while operating profit grew more modestly to KRW0.65 billion.

In 2026Q1, revenue fell back to KRW3.92 billion yet operating profit surged to KRW1.16 billion (roughly a 29.7% margin), reflecting the project-based mismatch between revenue and profit timing, and owners' net income reached KRW1.88 billion, the highest of the trailing four quarters.

In 2026Q2, revenue of KRW5.29 billion generated operating profit of KRW1.08 billion (about 20.4% margin), but owners' net income came in lower at KRW0.78 billion, underscoring how non-operating items repeatedly drive quarter-to-quarter swings in the bottom line.

Owners' net income summed over the trailing four quarters (2025Q3-2026Q2) reached KRW4.68 billion, suggesting profit scale has re-expanded on an annualized basis.

Demand for Linkgenesis's semiconductor and display equipment communication and verification software is ultimately tied to fab capital spending and equipment utilization rates.

Recent brokerage commentary in Korea projected that, with memory leading the way, the overall semiconductor market would post double-digit growth in 2026, and argued that after several lean years capital expenditure tone is strengthening, making front-end and back-end equipment makers worth watching.

SEMI has likewise forecast that global semiconductor manufacturing equipment sales in 2026 would rise sharply from the prior year to a record high, suggesting the investment cycle underpinning demand for equipment-related software is in a recovery phase.

Some forecasts also point to HBM stacking and advanced packaging proliferation as drivers of back-end equipment demand, which could increase the complexity of equipment communication and raise the need for SECS/GEM standard communication software.

In terms of competitive positioning, similar smart-factory and machine-vision software companies cited include Withtec, Grecter, RTM, and Ensys; as a software and solution provider rather than an equipment maker, Linkgenesis is not tied to any single large equipment vendor.

However, given its small scale, revenue can swing considerably based on individual capex decisions by customers or the timing of specific large project wins.

Through 2026 the company has participated in a series of major industry trade shows—the Smart Factory + Automation World (AW 2026), the AI & Big Data Show, and Smart Tech Korea (STK 2026)—showcasing its integrated operations automation platform EQlizer and AI vision solutions VLAD and VLAD Ops.

EQlizer was presented as a total equipment automation solution integrating software automation, hardware control, and AI edge recognition while supporting SECS/GEM standard communication for semiconductor and display equipment, with a non-invasive installation method that does not require replacing existing equipment cited as a key feature.

VLAD and VLAD Ops, built on more than 20 years of accumulated image analysis technology, aim to expand beyond quality inspection into industrial safety and security, with the company seeking to extend applications from semiconductor and display manufacturing into batteries and automotive production.

In earlier investor communications, management said it was in discussions to supply AI-based solutions to a large conglomerate affiliate, and whether these discussions are confirmed through disclosures or follow-up reporting is worth watching.

Management has also previously outlined longer-term ambitions to extend its AI inspection technology into the bio field, such as monitoring biological changes in animal and clinical trials.

That said, the revenue contribution or concrete order timing for these new initiatives has not yet been confirmed with published figures, so whether they translate into actual results will need to be tracked through future disclosures.